Robert Goeltz
Finanzdirektor/CFO bei ARCUS BIOSCIENCES, INC.
Vermögen: 227 667 $ am 30.04.2024
Profil
Robert C.
Goeltz is currently the Chief Financial Officer at Arcus Biosciences, Inc. He previously held the position of Finance Director at Tularik, Inc. from 2002 to 2004.
From 2013 to 2015, he served as the Chief Financial Officer at Onyx Pharmaceuticals, Inc. He then worked as the Chief Financial Officer & Senior Vice President at CytomX Therapeutics, Inc. from 2015 to 2017.
From 2017 to 2020, he was the Chief Financial Officer at Unity Biotechnology, Inc. Mr. Goeltz completed his undergraduate degree at Goizueta Business School-Emory and holds an MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0,02% | 01.03.2024 | 15 456 ( 0,02% ) | 227 667 $ | 30.04.2024 |
Aktive Positionen von Robert Goeltz
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Finanzdirektor/CFO | 01.08.2020 |
Ehemalige bekannte Positionen von Robert Goeltz
| Unternehmen | Position | Ende |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Finanzdirektor/CFO | 01.08.2020 |
| CYTOMX THERAPEUTICS, INC. | Finanzdirektor/CFO | 15.05.2017 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Finanzdirektor/CFO | 01.05.2015 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Finanzdirektor/CFO | 01.08.2004 |
Ausbildung von Robert Goeltz
| UCLA Anderson School of Management | Masters Business Admin |
| Goizueta Business School-Emory | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
